中国临床药理学杂志2025，Vol.41Issue(6)：881-885,5.DOI:10.13699/j.cnki.1001-6821.2025.06.025
司美格鲁肽临床使用的情况分析
Analysis of the clinical prescription of semaglutide
摘要
Abstract
Objective To investigate prescription of semaglutide and analyzed status of semaglutide administration in China's real-world.Methods The prescription including semaglutide were extracted from 9 cities across China in first quarter of 2023.We analyzed the current administration of semaglutide and risk factors of off-label use of semaglutide by multivariant logistic regression.Results A total of 10884 patients were included after data screening,about 70％patients were 34-64 years old.Endocrinology was the most common prescription department.Diabetes was diagnosed in 76.78％patients and 765 patients combined chronic complications of diabetes,of which diabetic neuropathy(470 cases,4.32％)and diabetic nephropathy(248 cases,2.28％)were the most common complications.Cardiovascular diseases and risk factors were diagnosed in 2429 patients.Hypertension(1379 cases,12.67％)and hyperlipemia(1342 cases,11.31％)were the most common cardiovascular disease and risk factors.While 56.74％(6176 cases)patients were treated by semaglutide singe-agent in general,36.79％(3075 cases/8357 cases)patients with diabetes combined oral hypoglycemic drugs or insulin,and biguanides and sodium-dependent glucose transporters 2 inhibitors were used mostly.About 1/4 patients without diabetes off-label administrated semaglutide.According to the logistic regression,risk factors of off-label use were elder age,came from first-tier cities,prescription from endocrinology and a greater number of combined cardiovascular diseases and risk factors.Conclusion Semaglutide-based therapy regimens in patients with diabetes are fairly standardized according to clinical guidelines,while off-label use in patients without diabetes are supported by clinical evidence and guidelines to some extent.关键词
司美格鲁肽/真实世界/超说明书用药Key words
semaglutide/real-world/off-label administration分类
医药卫生引用本文复制引用
张斌,侯珂露,陈月,张海英..司美格鲁肽临床使用的情况分析[J].中国临床药理学杂志,2025,41(6):881-885,5.基金项目
北京大学人民医院研究与发展基金资助项目(RDE2021-02) （RDE2021-02）
